The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Jean-Marie Michot | EHA 2018 | What are the key safety and efficacy outcomes of the CC-122 and obinutuzumab study in R/R B-cell NHL?

Jun 18, 2018

23rd Congress of European Hematology Association, 14-17 June 2018, Stockholm, Sweden
Jean-Marie Michot
Gustave Roussy Institute of Cancer, Villejuif, FR

Interview topic: What are the key safety and efficacy outcomes of the CC-122 and obinutuzumab study in R/R B-cell NHL?

What are the key safety and efficacy outcomes of the CC-122 and obinutuzumab study in R/R B-cell NHL?